** Shares of Australian Clinical Labs ACL.AX fall 18.9% to A$3, their lowest level since August 30, 2024
** Pathology services provider posts HY underlying NPAT of A$12.1 million ($7.68 million), below Visible Alpha consensus of A$15.5 million
** Co say it's on track to deliver FY25 underlying EBIT guidance in range of A$65 million to A$73 million, mid-point of which is lower than Visible Alpha consensus of A$71 million
** 1.1 million shares change hands, 2.1x the 30-day average of 527,734
** Stock down 12.8% YTD, including session's moves
($1 = 1.5748 Australian dollars)
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((Jasmeenaraislam.shaikh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.